Left ventricular lead placement in cardiac resynchronization therapy: where and how?

Cardiac resynchronization therapy (CRT) offers proven benefit to patients with refractory symptomatic chronic heart failure (New York Heart Association Class III or IV), severe left ventricular (LV) systolic dysfunction (LV ejection fraction 120 ms). Cardiac resynchronization therapy has the potenti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Europace (London, England) England), 2009-05, Vol.11 (5), p.554-561
Hauptverfasser: Khan, Fakhar Zaman, Virdee, Munmohan Singh, Fynn, Simon Patrick, Dutka, David Paul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 561
container_issue 5
container_start_page 554
container_title Europace (London, England)
container_volume 11
creator Khan, Fakhar Zaman
Virdee, Munmohan Singh
Fynn, Simon Patrick
Dutka, David Paul
description Cardiac resynchronization therapy (CRT) offers proven benefit to patients with refractory symptomatic chronic heart failure (New York Heart Association Class III or IV), severe left ventricular (LV) systolic dysfunction (LV ejection fraction 120 ms). Cardiac resynchronization therapy has the potential to improve survival and functional capacity, reduce hospital admissions, and promote LV reverse remodelling. Although difficult to truly evaluate, up to 30% of patients do not attain symptomatic benefit. Factors associated with a poor outcome include inappropriate patient selection, inadequate device programming, presence of myocardial scar, and suboptimal LV lead placement. Left ventricular dyssynchrony is an important determinant of CRT response, although at present no reliable single measure to identify patients beyond QRS width has been identified. In this review, we discuss the effect of LV lead placement to pace the region of maximal dyssynchrony, the impact of total scar burden on response, and the relationship between LV lead position and localized scar. Consideration is also given to prospectively defining placement of the LV lead including surgical epicardial lead positioning.
doi_str_mv 10.1093/europace/eup076
format Article
fullrecord <record><control><sourceid>proquest_TOX</sourceid><recordid>TN_cdi_proquest_miscellaneous_67183903</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/europace/eup076</oup_id><sourcerecordid>67183903</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-d2e9e442d26aa721ddeca9220b4a4a146fe9a64bd4a3d1225fbb2dfca7ad90673</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMo7rp69iY5eRDq5qMfxovI4hcseFnPZZpM2Urb1KR1WX-9kVY8epqX4ZmX4SHknLNrzpRc4uBsBxpD6FiWHpA5T6SIBFPiMGSmVJRwoWbkxPt3xlgmVHJMZlzJTHCezMlmjWVPP7HtXaWHGhytEQzt6lDahC2tWqrBmQo0dej3rd4621Zf0Fe2pf0WHXT7W7oLASm0hm7t7u6UHJVQezyb5oK8PT5sVs_R-vXpZXW_jrTMeB8ZgQrjWBiRAoR_jEENSghWxBADj9MSFaRxYWKQhguRlEUhTKkhA6NYmskFuRx7O2c_BvR93lReY11Di3bweZrxG6mYDOByBLWz3jss885VDbh9zln-IzL_FZmPIsPFxVQ9FA2aP34yF4CrEbBD92_bNx-AgnI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67183903</pqid></control><display><type>article</type><title>Left ventricular lead placement in cardiac resynchronization therapy: where and how?</title><source>Oxford Journals Open Access Collection</source><creator>Khan, Fakhar Zaman ; Virdee, Munmohan Singh ; Fynn, Simon Patrick ; Dutka, David Paul</creator><creatorcontrib>Khan, Fakhar Zaman ; Virdee, Munmohan Singh ; Fynn, Simon Patrick ; Dutka, David Paul</creatorcontrib><description>Cardiac resynchronization therapy (CRT) offers proven benefit to patients with refractory symptomatic chronic heart failure (New York Heart Association Class III or IV), severe left ventricular (LV) systolic dysfunction (LV ejection fraction &lt;35%), and LV dyssynchrony (QRS width &gt;120 ms). Cardiac resynchronization therapy has the potential to improve survival and functional capacity, reduce hospital admissions, and promote LV reverse remodelling. Although difficult to truly evaluate, up to 30% of patients do not attain symptomatic benefit. Factors associated with a poor outcome include inappropriate patient selection, inadequate device programming, presence of myocardial scar, and suboptimal LV lead placement. Left ventricular dyssynchrony is an important determinant of CRT response, although at present no reliable single measure to identify patients beyond QRS width has been identified. In this review, we discuss the effect of LV lead placement to pace the region of maximal dyssynchrony, the impact of total scar burden on response, and the relationship between LV lead position and localized scar. Consideration is also given to prospectively defining placement of the LV lead including surgical epicardial lead positioning.</description><identifier>ISSN: 1099-5129</identifier><identifier>EISSN: 1532-2092</identifier><identifier>DOI: 10.1093/europace/eup076</identifier><identifier>PMID: 19372115</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Cicatrix - physiopathology ; Defibrillators, Implantable ; Heart Conduction System - physiopathology ; Heart Failure - physiopathology ; Heart Failure - therapy ; Heart Ventricles - physiopathology ; Humans ; Pacemaker, Artificial ; Ventricular Dysfunction, Left - physiopathology ; Ventricular Dysfunction, Left - therapy</subject><ispartof>Europace (London, England), 2009-05, Vol.11 (5), p.554-561</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-d2e9e442d26aa721ddeca9220b4a4a146fe9a64bd4a3d1225fbb2dfca7ad90673</citedby><cites>FETCH-LOGICAL-c371t-d2e9e442d26aa721ddeca9220b4a4a146fe9a64bd4a3d1225fbb2dfca7ad90673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1604,27924,27925</link.rule.ids><linktorsrc>$$Uhttps://dx.doi.org/10.1093/europace/eup076$$EView_record_in_Oxford_University_Press$$FView_record_in_$$GOxford_University_Press</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19372115$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khan, Fakhar Zaman</creatorcontrib><creatorcontrib>Virdee, Munmohan Singh</creatorcontrib><creatorcontrib>Fynn, Simon Patrick</creatorcontrib><creatorcontrib>Dutka, David Paul</creatorcontrib><title>Left ventricular lead placement in cardiac resynchronization therapy: where and how?</title><title>Europace (London, England)</title><addtitle>Europace</addtitle><description>Cardiac resynchronization therapy (CRT) offers proven benefit to patients with refractory symptomatic chronic heart failure (New York Heart Association Class III or IV), severe left ventricular (LV) systolic dysfunction (LV ejection fraction &lt;35%), and LV dyssynchrony (QRS width &gt;120 ms). Cardiac resynchronization therapy has the potential to improve survival and functional capacity, reduce hospital admissions, and promote LV reverse remodelling. Although difficult to truly evaluate, up to 30% of patients do not attain symptomatic benefit. Factors associated with a poor outcome include inappropriate patient selection, inadequate device programming, presence of myocardial scar, and suboptimal LV lead placement. Left ventricular dyssynchrony is an important determinant of CRT response, although at present no reliable single measure to identify patients beyond QRS width has been identified. In this review, we discuss the effect of LV lead placement to pace the region of maximal dyssynchrony, the impact of total scar burden on response, and the relationship between LV lead position and localized scar. Consideration is also given to prospectively defining placement of the LV lead including surgical epicardial lead positioning.</description><subject>Cicatrix - physiopathology</subject><subject>Defibrillators, Implantable</subject><subject>Heart Conduction System - physiopathology</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - therapy</subject><subject>Heart Ventricles - physiopathology</subject><subject>Humans</subject><subject>Pacemaker, Artificial</subject><subject>Ventricular Dysfunction, Left - physiopathology</subject><subject>Ventricular Dysfunction, Left - therapy</subject><issn>1099-5129</issn><issn>1532-2092</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMo7rp69iY5eRDq5qMfxovI4hcseFnPZZpM2Urb1KR1WX-9kVY8epqX4ZmX4SHknLNrzpRc4uBsBxpD6FiWHpA5T6SIBFPiMGSmVJRwoWbkxPt3xlgmVHJMZlzJTHCezMlmjWVPP7HtXaWHGhytEQzt6lDahC2tWqrBmQo0dej3rd4621Zf0Fe2pf0WHXT7W7oLASm0hm7t7u6UHJVQezyb5oK8PT5sVs_R-vXpZXW_jrTMeB8ZgQrjWBiRAoR_jEENSghWxBADj9MSFaRxYWKQhguRlEUhTKkhA6NYmskFuRx7O2c_BvR93lReY11Di3bweZrxG6mYDOByBLWz3jss885VDbh9zln-IzL_FZmPIsPFxVQ9FA2aP34yF4CrEbBD92_bNx-AgnI</recordid><startdate>200905</startdate><enddate>200905</enddate><creator>Khan, Fakhar Zaman</creator><creator>Virdee, Munmohan Singh</creator><creator>Fynn, Simon Patrick</creator><creator>Dutka, David Paul</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200905</creationdate><title>Left ventricular lead placement in cardiac resynchronization therapy: where and how?</title><author>Khan, Fakhar Zaman ; Virdee, Munmohan Singh ; Fynn, Simon Patrick ; Dutka, David Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-d2e9e442d26aa721ddeca9220b4a4a146fe9a64bd4a3d1225fbb2dfca7ad90673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Cicatrix - physiopathology</topic><topic>Defibrillators, Implantable</topic><topic>Heart Conduction System - physiopathology</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - therapy</topic><topic>Heart Ventricles - physiopathology</topic><topic>Humans</topic><topic>Pacemaker, Artificial</topic><topic>Ventricular Dysfunction, Left - physiopathology</topic><topic>Ventricular Dysfunction, Left - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Fakhar Zaman</creatorcontrib><creatorcontrib>Virdee, Munmohan Singh</creatorcontrib><creatorcontrib>Fynn, Simon Patrick</creatorcontrib><creatorcontrib>Dutka, David Paul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Europace (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Khan, Fakhar Zaman</au><au>Virdee, Munmohan Singh</au><au>Fynn, Simon Patrick</au><au>Dutka, David Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Left ventricular lead placement in cardiac resynchronization therapy: where and how?</atitle><jtitle>Europace (London, England)</jtitle><addtitle>Europace</addtitle><date>2009-05</date><risdate>2009</risdate><volume>11</volume><issue>5</issue><spage>554</spage><epage>561</epage><pages>554-561</pages><issn>1099-5129</issn><eissn>1532-2092</eissn><abstract>Cardiac resynchronization therapy (CRT) offers proven benefit to patients with refractory symptomatic chronic heart failure (New York Heart Association Class III or IV), severe left ventricular (LV) systolic dysfunction (LV ejection fraction &lt;35%), and LV dyssynchrony (QRS width &gt;120 ms). Cardiac resynchronization therapy has the potential to improve survival and functional capacity, reduce hospital admissions, and promote LV reverse remodelling. Although difficult to truly evaluate, up to 30% of patients do not attain symptomatic benefit. Factors associated with a poor outcome include inappropriate patient selection, inadequate device programming, presence of myocardial scar, and suboptimal LV lead placement. Left ventricular dyssynchrony is an important determinant of CRT response, although at present no reliable single measure to identify patients beyond QRS width has been identified. In this review, we discuss the effect of LV lead placement to pace the region of maximal dyssynchrony, the impact of total scar burden on response, and the relationship between LV lead position and localized scar. Consideration is also given to prospectively defining placement of the LV lead including surgical epicardial lead positioning.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>19372115</pmid><doi>10.1093/europace/eup076</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1099-5129
ispartof Europace (London, England), 2009-05, Vol.11 (5), p.554-561
issn 1099-5129
1532-2092
language eng
recordid cdi_proquest_miscellaneous_67183903
source Oxford Journals Open Access Collection
subjects Cicatrix - physiopathology
Defibrillators, Implantable
Heart Conduction System - physiopathology
Heart Failure - physiopathology
Heart Failure - therapy
Heart Ventricles - physiopathology
Humans
Pacemaker, Artificial
Ventricular Dysfunction, Left - physiopathology
Ventricular Dysfunction, Left - therapy
title Left ventricular lead placement in cardiac resynchronization therapy: where and how?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A20%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_TOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Left%20ventricular%20lead%20placement%20in%20cardiac%20resynchronization%20therapy:%20where%20and%20how?&rft.jtitle=Europace%20(London,%20England)&rft.au=Khan,%20Fakhar%20Zaman&rft.date=2009-05&rft.volume=11&rft.issue=5&rft.spage=554&rft.epage=561&rft.pages=554-561&rft.issn=1099-5129&rft.eissn=1532-2092&rft_id=info:doi/10.1093/europace/eup076&rft_dat=%3Cproquest_TOX%3E67183903%3C/proquest_TOX%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67183903&rft_id=info:pmid/19372115&rft_oup_id=10.1093/europace/eup076&rfr_iscdi=true